{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:32:31Z","timestamp":1792852351123,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00520-023-08222-3","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:02:46Z","timestamp":1703030566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["2023 updated MASCC\/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-3428","authenticated-orcid":false,"given":"Florian","family":"Scott\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Hesketh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"8222_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00520-004-0718-y","volume":"13","author":"SM Grunberg","year":"2005","unstructured":"Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, Du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2014an update. Support Care Cancer 13:80\u201384. https:\/\/doi.org\/10.1007\/s00520-004-0718-y","journal-title":"Support Care Cancer"},{"key":"8222_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00520-016-3365-1","volume":"25","author":"F Roila","year":"2017","unstructured":"Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer 25:289\u2013294. https:\/\/doi.org\/10.1007\/s00520-016-3365-1","journal-title":"Support Care Cancer"},{"key":"8222_CR3","doi-asserted-by":"crossref","unstructured":"Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Ruhlmann CH, Sayegh P, Hesketh PJ (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents \u2013Updated MASCC\/ESMO consensus recommendation. Support Care Cancer 21:xx-yy","DOI":"10.1007\/s00520-023-08220-5"},{"key":"8222_CR4","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzieJE. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372: n71 https:\/\/doi.org\/10.1136\/bmj.n71:10.1136\/bmj.n71)","DOI":"10.1136\/bmj.n71:10.1136\/bmj.n71)"},{"key":"8222_CR5","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, lihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, ZhangL, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scott\u00e9 F. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO OPEN XXX"},{"key":"8222_CR6","doi-asserted-by":"publisher","unstructured":"Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, Powers D, Aapro M. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 2016;122:2418-25. Erratum: Cancer 2016;122:3579.https:\/\/doi.org\/10.1002\/cncr.30054","DOI":"10.1002\/cncr.30054"},{"key":"8222_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"H Yahata","year":"2016","unstructured":"Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y, Nishida M, Masuda S, Kato K (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21:491\u2013497. https:\/\/doi.org\/10.1007\/s10147-015-0928-y","journal-title":"Int J Clin Oncol"},{"key":"8222_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","volume":"26","author":"K Jordan","year":"2018","unstructured":"Jordan K, Bl\u00e4ttermann L, Hinke A, M\u00fcller-Tidow C, Jahn F (2018) Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? -a systematic review and meta-analysis. Support Care Cancer 26:21\u201332. https:\/\/doi.org\/10.1007\/s00520-017-3857-7","journal-title":"Support Care Cancer"},{"key":"8222_CR9","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2217\/fon-2017-0712","volume":"14","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Hou X, Zhang R, Chen G, Huang Y, Yang Y, Zhao Y, Fang W, Hong S, Kang S, Zhou T, Zhang Z, Chen X, Zhang L (2018) Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis. Future Oncol 14:1933\u20131941. https:\/\/doi.org\/10.2217\/fon-2017-0712","journal-title":"Future Oncol"},{"key":"8222_CR10","doi-asserted-by":"publisher","unstructured":"Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S, Sakai D, Uemura M, Hata T, Takemasa I, Mizushima T, Ohno Y, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M, Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group(MCSGO) (2015) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274\u20131282. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.024","DOI":"10.1016\/j.ejca.2015.03.024"},{"key":"8222_CR11","doi-asserted-by":"publisher","unstructured":"Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R, Ikenaga M, Ikeda M, Yamamoto H, Satoh T, Hata T, Takemasa I, Mizushima T, Doki Y, Mori M. Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO) (2017) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol 22:88\u201395. https:\/\/doi.org\/10.1007\/s10147-016-1022-9","DOI":"10.1007\/s10147-016-1022-9"},{"issue":"4","key":"8222_CR12","doi-asserted-by":"publisher","first-page":"e215250","DOI":"10.1001\/jamanetworkopen.2021.5250","volume":"4","author":"DS Wang","year":"2021","unstructured":"Wang DS, Hu MT, Wang ZQ, Ren C, Qiu MZ, Luo HY, Jin Y, Fong WP, Wang SB, Peng JW, Zou QF, Tan Q, Wang FH, Li YH (2021) Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw Open 4(4):e215250. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.5250","journal-title":"JAMA Netw Open"},{"key":"8222_CR13","doi-asserted-by":"publisher","first-page":"101480","DOI":"10.1016\/j.eclinm.2022.101480","volume":"49","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Wu Z, Shi L, Shen C, Zhang J, Hu H, Li W, Cai Y, Xie X, Ling J, Zheng Q, Deng Y (2022) Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: a randomized, open-label, phase 3 trial. EclinicalMedicine 49:101480. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101480","journal-title":"EclinicalMedicine"},{"key":"8222_CR14","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1093\/oncolo\/oyac060","volume":"27","author":"D Watanabe","year":"2022","unstructured":"Watanabe D, Iihara H, Fujii H, Makiyama A, Nishida S, Suzuki A (2022) One-day versus three-day dexamethasone with NK1RA for patients receiving carboplatin and moderate emetogenic chemotherapy: a network meta-analysis. Oncologist 27:e524\u2013e532. https:\/\/doi.org\/10.1093\/oncolo\/oyac060","journal-title":"Oncologist"},{"key":"8222_CR15","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","volume":"24","author":"Y Okada","year":"2019","unstructured":"Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S, Komatsu Y, Celio L, Aapro M (2019) One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. Oncologist 24:1593\u20131600. https:\/\/doi.org\/10.1634\/theoncologist.2019-0133","journal-title":"Oncologist"},{"key":"8222_CR16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/cas.12675","volume":"106","author":"Y Komatsu","year":"2015","unstructured":"Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y (2015) Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetron. Cancer Sci 106:891\u2013895. https:\/\/doi.org\/10.1111\/cas.12675","journal-title":"Cancer Sci"},{"key":"8222_CR17","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s00520-015-2760-3","volume":"23","author":"N Furukawa","year":"2015","unstructured":"Furukawa N, Kanayama S, Tanase Y, Ito F (2015) Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin. Support Care Cancer 23:3317\u20133322. https:\/\/doi.org\/10.1007\/s00520-015-2760-3","journal-title":"Support Care Cancer"},{"key":"8222_CR18","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/jog.12748","volume":"41","author":"M Matsuura","year":"2015","unstructured":"Matsuura M, Satohisa S, Teramoto M, Tanaka R, Iwasaki M, Nishikawa A, Mizunuma M, Tanaka S, Hayakawa O, Saito T (2015) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: a randomized, multicenter, phase-II trial. J Obstet Gynaecol Res 41:1607\u20131613. https:\/\/doi.org\/10.1111\/jog.12748","journal-title":"J Obstet Gynaecol Res"},{"key":"8222_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/0300891619839301","volume":"105","author":"L Celio","year":"2019","unstructured":"Celio L, Saibene G, Lepori S, Festinese F, Niger M, Raspagliesi F, Lorusso D (2019) Short-course olanzapine to prevent delayed emesis following carboplatin\/paclitaxel for gynecologic cancer: a randomized study. Tumori 105:253\u2013258. https:\/\/doi.org\/10.1177\/0300891619839301","journal-title":"Tumori"},{"key":"8222_CR20","unstructured":"Antiemesis. Version 2.2022. National Comprehensive Cancer Network\u00ae (NCCN)."},{"key":"8222_CR21","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"8222_CR22","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy induced nausea and vomiting. Ann Oncol 28:1260\u20131267. https:\/\/doi.org\/10.1093\/annonc\/mdx100","journal-title":"Ann Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08222-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T21:26:59Z","timestamp":1708032419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08222-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["8222"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08222-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"1 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The correct family name should be: Iihara","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Florian Scott\u00e9 declares he has received honoraria from Sanofi, Sandoz, Roche, MSD, Prostrakan, Leo Pharma, Janssen, AMGEN, Pierre Fabre Oncologie, Vifor Pharma, Arrow, Pfizer, BMS, Bayer, Thermo Fisher, Pharmanovia, Gilead, Viatris, and Helsinn.Lee Schwartzberg declares he has received honoraria from Helsinn, GlaxoSmithKline, and Pfizer.Hirotoshi Iihara declares that he has received personal fees from Taiho, Chugai, Yakult, Astellas, Eli Lilly, Daiichi Sankyo, AstraZeneca, Nippon Kayaku, Ono, and Nippon Boehringer Ingelheim and consulting fees for their institution from Taiho and Eisai outside the submitted work.Matti Aapro declares the following interests relevant to this manuscript: has received honoraria from Berlin-Chemie, Fosun, Helsinn Healthcare SA, Juniper Biologics, Knight Therapeutics, Mundipharma International Limited, and Vifor Pharma.Richard Gralla declares the following interests relevant to this manuscript: has received honoraria from Fosun, Helsinn Healthcare SA, Juniper Biologics, Knight Therapeutics, Mundipharma International Limited, and Vifor Pharma.Paul J Hesketh declares that he has no financial interests.Karin Jordan reports personal fees as an invited speaker from Amgen, Art Tempi, Helsinn Healthcare SA, Hexal, Med Update GmbH, MSD, Mundipharma, Onkowissen, Esteve, Roche, Shire (Takeda), and Vifor; personal fees for advisory board membership from Amgen, AstraZeneca, BD Solutions, Hexal, Karyopharm, and Voluntis; and personal fees as author for UpToDate.Ronald Chow declares that he has no financial interests.J\u00f8rn Herrstedt declares he has received honoraria from Pharmathen S.A.The other authors have no relevant financial or non-financial interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"45"}}